| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by …
Over the last 12 months, insiders at Arbutus Biopharma Corp have bought $0 and sold $0 worth of Arbutus Biopharma Corp stock.
On average, over the past 5 years, insiders at Arbutus Biopharma Corp have bought $0 and sold $460,381 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $13,900 was made by HENRIQUES RICHARD C JR (director) on 2015‑08‑24.
| 2025-02-04 | Sale | McElhaugh Michael J. | Interim President & CEO | 23,790 0.0126% | $3.28 | $78,103 | +4.46% | |
| 2025-02-04 | Sale | HASTINGS DAVID C | Chief Financial Officer | 22,183 0.0117% | $3.28 | $72,827 | +4.46% | |
| 2025-02-04 | Sale | Sims Karen | Chief Medical Officer | 19,348 0.0102% | $3.28 | $63,519 | +4.46% | |
| 2025-02-04 | Sale | Naftzger J. Christopher | General Counsel and CCO | 11,333 0.006% | $3.28 | $37,206 | +4.46% | |
| 2024-08-14 | Sale | MANCHESTER KEITH S | director | 8,846 0.0048% | $3.69 | $32,637 | -7.34% | |
| 2024-02-02 | Sale | McElhaugh Michael J. | Interim President & CEO | 10,164 0.0057% | $2.31 | $23,504 | +40.76% | |
| 2024-02-02 | Sale | Sofia Michael J. | Chief Scientific Officer | 9,982 0.0056% | $2.31 | $23,083 | +40.76% | |
| 2024-02-02 | Sale | HASTINGS DAVID C | Chief Financial Officer | 9,593 0.0054% | $2.31 | $22,184 | +40.76% | |
| 2024-02-02 | Sale | Sims Karen | Chief Medical Officer | 4,358 0.0024% | $2.31 | $10,078 | +40.76% | |
| 2021-12-01 | Sale | Sofia Michael J. | Chief Scientific Officer | 200,000 0.218% | $5.09 | $1.02M | -44.14% | |
| 2021-02-09 | Sale | McElhaugh Michael J. | Chief Business Officer | 20,000 0.0239% | $5.00 | $100,000 | -25.28% | |
| 2020-12-14 | Sale | McElhaugh Michael J. | Chief Business Officer | 40,000 0.0439% | $5.00 | $200,032 | -29.51% | |
| 2020-07-23 | Sale | McElhaugh Michael J. | Chief Business Officer | 20,000 0.0203% | $5.01 | $100,200 | -46.45% | |
| 2018-08-13 | Sale | Sofia Michael J. | Chief Scientific Officer | 4,250 0.0076% | $9.51 | $40,436 | -60.00% | |
| 2018-07-11 | Sale | Sofia Michael J. | Chief Scientific Officer | 10,000 0.017% | $10.00 | $100,000 | -61.98% | |
| 2018-07-09 | Sale | Sofia Michael J. | Chief Scientific Officer | 10,000 0.0183% | $8.91 | $89,060 | -53.41% | |
| 2018-07-06 | Sale | Sofia Michael J. | Chief Scientific Officer | 10,000 0.0166% | $8.45 | $84,500 | -55.27% | |
| 2018-07-05 | Sale | Sofia Michael J. | Chief Scientific Officer | 10,000 0.0167% | $8.40 | $84,000 | -54.73% | |
| 2018-07-03 | Sale | Sofia Michael J. | Chief Scientific Officer | 10,000 0.0174% | $8.00 | $80,000 | -50.24% | |
| 2017-10-03 | Sale | Sofia Michael J. | Chief Scientific Officer | 20,000 0.0392% | $8.00 | $160,000 | -21.85% |
| HENRIQUES RICHARD C JR | director | 1000 0.0005% | $3,880.00 | 1 | 0 | <0.0001% |
$100,473,344 | 83 | 9.53% | $826.91M | |
$5,911,307 | 70 | -1.38% | $884.8M | |
$1,108,102,085 | 66 | 36.91% | $755.04M | |
$59,156,363 | 22 | 29.25% | $686.5M | |
$22,365,077 | 19 | -27.47% | $674.89M |
| Increased Positions | 77 | +44% | 13M | +11.03% |
| Decreased Positions | 62 | -35.43% | 9M | -7.99% |
| New Positions | 22 | New | 1M | New |
| Sold Out Positions | 17 | Sold Out | 5M | Sold Out |
| Total Postitions | 190 | +8.57% | 122M | +3.04% |
| Morgan Stanley | $116,629.00 | 12.74% | 24.45M | +288,229 | +1.19% | 2025-09-30 |
| Whitefort Capital Management, Lp | $63,647.00 | 6.95% | 13.34M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $60,472.00 | 6.6% | 12.68M | -191,790 | -1.49% | 2025-09-30 |
| Two Seas Capital Lp | $52,428.00 | 5.73% | 10.99M | +547,944 | +5.25% | 2025-09-30 |
| Vanguard Group Inc | $42,887.00 | 4.68% | 8.99M | -94,004 | -1.03% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $23,921.00 | 2.61% | 5.01M | +2M | +94.68% | 2025-09-30 |
| State Street Corp | $19,549.00 | 2.13% | 4.1M | -361,444 | -8.11% | 2025-09-30 |
| Geode Capital Management, Llc | $17,488.00 | 1.91% | 3.67M | +29,141 | +0.8% | 2025-09-30 |
| Adar1 Capital Management, Llc | $13,848.00 | 1.51% | 2.9M | +77,453 | +2.74% | 2025-09-30 |
| Goldman Sachs Group Inc | $10,367.00 | 1.13% | 2.17M | -866,353 | -28.5% | 2025-09-30 |